Date:               April 10, 2020

TO:                  info@kedemnatural.com – Herbs of Kedem
yaromeran@gmail.com

RE:                 Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address http://kedemnatural.com on March 31, 2020, and April 9, 2020, respectively. The FDA has observed that your website offers herbal products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.1 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.2 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include:

- “Corona Virus Prevention . . . As long as there is no vaccine for this new virus, it is recommended to consider using natural substances . . . Since plants deal with plant viruses, they sometimes produce substances that can be effective against other viruses as well . . . . Recommended products . . . ORANIT . . . TAHAR . . . NIKUZIT . . . EZQVIT . . . KALITA . . . oral spray . . . when experiencing a sore throat.” [from your website http://kedemnatural.com/categories/corona-virus-covid19.html]

---

1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).
• “Corona Virus Prevention . . . Kalita – Throat Inflammations spray . . . Also effective for thorough
treatment of internal inflammations such as lungs . . . for strong throat inflammation: 3-5 sprays in
the throat each time” [from your website http://kedemnatural.com/categories/corona-virus-
covid19/kalita.html]

• “Corona Virus Prevention . . . Tahar – Natural Disinfectant Spray . . . suitable for spraying
disinfections: disinfecting hands.” http://kedemnatural.com/categories/corona-virus-
covid19/tahar.html

• Various product website URLs contain “corona-virus-covid19”. For example:

• In the description of the product Winter Companion you state, “[i]n China, the novel corona virus
has been slowed down significantly . . . use was made of the composition Jinhua Qinggan, which
contains among other things, extractions of Japanese honeysuckle [an ingredient of your Winter
Companion product] . . . The use of the preparation in Corona patients has been reported to
shorten the healing time by about two and a half days.” [from your website
http://kedemnatural.com/food-supplements/winter-companion-dietary-supplement-for-flues-corona-
prevention.html]

• You link to a study about Withania somnifera, an ingredient in “Winter Companion,” and state,
  “Recent studies in India have shown that the vitamin, an intoxicating plant, may inhibit the
  attachment of the new corona virus to cells in the body.” [from your website
http://kedemnatural.com/food-supplements/winter-companion-dietary-supplement-for-flues-corona-
prevention.html]

You should take immediate action to correct the violations cited in this letter. This letter is not meant to be
an all-inclusive list of violations that exist in connection with your products or operations. It is your
responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's
implementing regulations. We advise you to review your websites, product labels, and other labeling and
promotional materials to ensure that you are not misleadingly representing your products as safe and
effective for a COVID-19-related use for which they have not been approved by FDA and that you do not
make claims that misbrand the products in violation of the FD&C Act. **Within 48 hours, please send an
email to COVID-19-Task-Force-CDER@fda.hhs.gov** describing the specific steps you have taken to
correct these violations. Include an explanation of each step being taken to prevent the recurrence of
violations, as well as copies of related documentation. Failure to immediately correct the violations cited in
this letter may result in legal action, including, without limitation, seizure and injunction.

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared,
or authorized by FDA and that are being misleadingly represented as safe and/or effective for the
treatment or prevention of COVID-19. Your firm will be added to a published list on FDA's website of firms
and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19
related products in violation of the FD&C Act. This list can be found at
Once you have taken corrective actions to cease the sale of your unapproved and unauthorized products
for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been
confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate
corrective action.

If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within
which you will complete the corrections. If you believe that your products are not in violation of the FD&C
Act, include your reasoning and any supporting information for our consideration.
If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.

Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.

In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely,

Donald D. Ashley
Director
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

Sincerely,

Richard A. Quaresima
Acting Associate Director
Division of Advertising Practices
Federal Trade Commission